MAPK1 and neoplasm: The second generation of cell permeable RAS antibody in human IgG1 format (pan-RAS iMab, inRas37) showing favorable PK in vivo with half-life of 3.5 days, only interacts with ATP-bound active RAS mutants but not wild type RAS, attenuates ERK and AKT signaling and suppresses tumor growth in several KRAS mutant (G12D, G12V, G13D, etc.)xenograft models 52.